期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 18, 期 2, 页码 165-180出版社
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2018.1428089
关键词
Biomarkers; traumatic brain injury; diagnostics; theranostics; neurotrauma
类别
资金
- U.S. DOD TED Seed Project [TED1506]
- NIH [R21NS085455-01, RC2 NS069409, 1U01 NS086090-01]
- VA [I01 RX001859-02]
- Florida State/McKnight Brain Institute BSCIRT Fund [110587]
- DOD [W81XWH-14-2-0176, W81XWH-13-1-04]
- DOD-Army [W81XWH-14-2-0166]
- European Commission [602150-2]
Introduction: Traumatic brain injury (TBI) is a major worldwide neurological disorder of epidemic proportions. To date, there are still no FDA-approved therapies to treat any forms of TBI. Encouragingly, there are emerging data showing that biofluid-based TBI biomarker tests have the potential to diagnose the presence of TBI of different severities including concussion, and to predict outcome.Areas covered: The authors provide an update on the current knowledge of TBI biomarkers, including protein biomarkers for neuronal cell body injury (UCH-L1, NSE), astroglial injury (GFAP, S100B), neuronal cell death (II-spectrin breakdown products), axonal injury (NF proteins), white matter injury (MBP), post-injury neurodegeneration (total Tau and phospho-Tau), post-injury autoimmune response (brain antigen-targeting autoantibodies), and other emerging non-protein biomarkers. The authors discuss biomarker evidence in TBI diagnosis, outcome prognosis and possible identification of post-TBI neurodegernative diseases (e.g. chronic traumatic encephalopathy and Alzheimer's disease), and as theranostic tools in pre-clinical and clinical settings.Expert commentary: A spectrum of biomarkers is now at or near the stage of formal clinical validation of their diagnostic and prognostic utilities in the management of TBI of varied severities including concussions. TBI biomarkers could serve as a theranostic tool in facilitating drug development and treatment monitoring.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据